According to the new market research report ”  Drug Screening Market by Product (Consumables, Urine testing devices, Analytical, Breathalyzer, Chromatography) & Services, Sample Type (Urine, Breath), End User (Workplace, Laboratories, Criminal Justice, Hospitals) – Global Forecast to 2025″, published by MarketsandMarkets™ , global drug screening market is projected to reach USD 10.0 billion by 2025, from USD 4.5 billion in 2020, at a CAGR of 17.3%.Major Growth Drivers:Growth in this market is attributed to the rising drug & alcohol consumption, the enforcement of stringent laws mandating drug and alcohol testing, government funding in major markets, and regulatory approvals and product and service launches.On the other hand, bans on alcohol consumption in Islamic countries and the prohibition of drug testing at workplaces in certain regions are some major factors that may hinder the market growth.The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.

This study involved four major activities in estimating the current size of the drug screening market.

Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market.Expected Revenue Growth:[192 Pages Report] The global drug screening market is projected to reach USD 10.0 billion by 2025, from USD 4.5 billion in 2020, at a CAGR of 17.3%.COVID-19 impact on the drug screening marketCOVID-19 has resulted in significant disruptions to businesses and economic activities globally and is expected to have a short-term negative impact on the drug screening market due to limited or non-availability of medical facilities/treatment centers, harm reduction service providers, and the fear of infection transmission.

To reduce the strain on the healthcare system and decrease disease transmission, various governments worldwide provided guidelines to postpone or delay non-essential medical and surgical procedures.Browse in-depth TOC on “Drug Screening Market”192 – Tables35 – Figures192 – PagesDownload PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=162987773The rapid testing devices segment will witness the highest growth during the forecast period.Based on product, the drug screening market is segmented into analytical instruments, rapid testing devices, and consumables.

Rapid testing devices market is further subsegmented into urine testing devices and oral fluid testing devices.

The urine testing devices segment is expected to account for the largest market share in 2019.

According to our findings, the residential air purifiers market is expected to grow at an approximate CAGR of 8-10% during the next two years.

According to our analysis, the below factors are playing a key role in shaping the growth of the global market.The growing awareness among consumers regarding air purification in the wake of COVID-19 is an opportunity for air purifier retailers to scale up their sales.

Some companies are increasing the production of air quality systems with the addition of different technologies such as High-Efficiency Particulate Air (HEPA) filters, photocatalytic purifiers, activated carbon purifiers, and ionic filters.

[131 Pages Report] The residential air purifiers market is projected to reach USD 13.6 billion by 2025 from USD 9.2 billion in 2020, at a CAGR of 8.2% during the forecast period.The growth of this market is majorly driven by the growing popularity of smart homes, supportive government regulations for effective air pollution monitoring and control, increasing public-private funding for effective air pollution monitoring, rising levels of air pollution worldwide, and increasing public awareness related to the healthcare and environmental implications of air pollution.Also, the need for an energy-efficient air purifier and R being undertaken to bring innovative products to the market is aiding the market growth.

However, the high cost of these products and technical limitations associated with air quality monitoring products are expected to restrain the growth of this market during the forecast period.Market DynamicsGrowing popularity of smart homesIncreasing urbanization and indoor air pollutionSupportive government regulations for effective air pollution monitoring and controlIncreasing public awareness pertaining to the healthcare implications of air pollutionCOVID-19 Impact on Global Residential Air Purifiers MarketThe COVID-19 outbreak has generated major remunerative opportunities for air purifier manufacturers, with high-performance units, comprising HEPA and activated carbon technologies, being highly popular, to minimize the spread of the virus for enclosed spaces.

Premium, high-performance air purifiers are capable of filtering out particles up to 1 micron, and the size of the COVID-19 virus is estimated to be around 1.2 microns.

COVID-19 has disrupted healthcare services in most countries worldwide; the worst affected are the US, Russia, Spain, Italy, the UK, India, Germany, and Iran.Immunofluorescence assays are used extensively for the detection of viral antigens, including COVID-19.

As a result, the pandemic has increased the demand for immunofluorescence assay products across the globe.

These are fast and simple methods that allow researchers to visualize the effects and dynamics of viral infections.

In the current global scenario, such methods represent a crucial tool in preventing and treating these pathogens.Download a PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=255585571The growth in this market is primarily attributed to the increasing prevalence of chronic diseases and rising R spending & healthcare expenditure.

Emerging markets are expected to provide growth opportunities for players operating in the immunofluorescence assays market in the coming years.

However, quality concerns over antibodies are the major challenge in this market.The global immunofluorescence assays market is projected to reach USD 3.5 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 6.0% during the forecast period.Reagents accounted for the larger share of the share of global immunofluorescence assays market in 2020 By product, the immunofluorescence assays market is segmented into reagents, instruments, antibodies, kits, and consumables and accessories.

The overall market, by public health organization is positively impacted by factors such as the growing expenditure on drugs and medical devices by public health organizations, government initiatives to strengthen analytical testing capabilities, increasing number of drug approvals & clinical trials, and rising demand for specialized analytical testing services.

However, complex and innovative pharmaceutical products requiring a distinctive analytical testing approach is the major challenge hampering the growth of government support on analytical laboratory services.

[68 Pages Report] The global analytical laboratory services market, by public health organization is projected to reach USD 333.8 Million by 2021 from USD 202.8 Million in 2016, at a CAGR of around 10.5% during the forecast period.The key trends for increase in market, by public health organization are the growing expenditure on drugs and medical devices by public health organizations, steps by the government to build up strong analytical testing abilities, increasing number of drug approvals and clinical trials, and rising demand for specialized analytical testing services.

However, complex and innovative pharmaceutical products requiring a distinctive analytical testing approach is the major challenge hampering the growth of government support.Market DynamicsGrowing Expenditure on Drugs and Medical Devices By Public OrganizationsGovernment Initiatives to Strengthen Analytical Testing CapabilitiesIncreasing Number of Drug Approvals and Clinical TrialsRising Demand for Specialized Analytical Testing ServicesOn the basis of type of service, the spend assessment is segmented into eight segments, namely, bioanalytical testing, batch release testing, stability testing, raw material testing, physical characterization, method validation, microbial testing, and environmental monitoring.Download PDF Brochure @   https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65590498This growth can be attributed to factors such as the usage and development of a large number of macromolecules and Biosimilars for various therapeutic areas and the growing biopharmaceutical industry across the globe.

The spending on batch release testing services is expected to account for the second largest share during the forecast period.

The growth can be attributed to the need for checking and validating the process for product development among pharmaceutical & biopharmaceutical companies and the increasing usage of dissolution test in the development and approval of generic solid oral dosage forms.The geographical regions mapped in the report are:North AmericaEuropeGermanyAsia-PacificRest of the World (RoW)Geographically, the market, by public health organization is segmented into North America, Europe, Asia-Pacific, and the Rest of the World (RoW).

According to the new market research report “Infectious Disease Diagnostics Market by Product (Reagents, Assays, Instrument), Test (Laboratory, POC), Technology (Immunodiagnostics, Microbiology, PCR, NGS, INAAT), Disease (COVID-19, Hepatitis, HAI, HIV, Influenza), End User – Global Forecast to 2026″, published by MarketsandMarkets™, the market is projected to reach USD 39.8 billion by 2026 from USD 28.1 billion in 2021, at a 7.2% CAGR.Browse in-depth TOC on “Infectious Disease Diagnostics Market”147 – Tables45 – Figures263 – PagesThe global prevalence of infectious diseases & onset of COVID-19 and the growing awareness for early disease diagnosis shift in focus from centralized laboratories to decentralized POC testing and rising technological advancements are factors supporting the growth of this market.

Growth opportunities in growing economies provide lucrative opportunities for the players operating in the market.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589COVID-19 Impact on Global Infectious Disease Diagnostics MarketCOVID-19 is an infectious disease caused by the most recently discovered novel coronavirus.

Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 moved from a regional crisis to a global pandemic in just a matter of a few weeks.

The COVID-19 pandemic negatively affected the overall sales of most of the companies but had an positive impact on the infectious disease diagnostics market because of the use of infectious disease diagnostic methods for COVID-19 testing.

Lockdowns resulting from the COVID-19 pandemic caused people to delay undergoing health checkups, thus affecting the number of tests being performed and sales of reagents.The reagents, kits, and consumables segment accounted for the largest share of the market, by product & service segment, in 2020Based on product & service, the infectious disease diagnostics market is segmented into reagents, kits, and consumables; instruments; and software & services.

This can be attributed to the need to closely monitor patient conditions and advantages such as faster diagnosis.The COVID-19 segment accounted for the largest share of the infectious disease diagnostics market, by disease type segment, in 2020Based on disease type, the market is segmented into COVID-19, HIV, HAIs, hepatitis, CT/NG, HPV, TB, influenza, and other infectious diseases.

According to the new market research report “Synthetic Biology Market by Tools (Oligonucleotides, Enzymes, Synthetic Cells), Technology (Gene Synthesis, Genome Engineering), Application (Tissue Regeneration, Biofuel, Consumer Care, Food & Agriculture, Environmental) and Region – Global Forecast to 2026″, published by MarketsandMarkets™, the global market size is projected to reach USD 30.7 billion by 2026 from USD 9.5 billion in 2021, at a CAGR of 26.5% during the forecast period.Browse in-depth TOC on “Synthetic Biology Market”452 – Tables39 – Figures377 – PagesDownload PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=889COVID-19 impact on the synthetic biology marketMany established pharmaceutical and biopharmaceutical companies, along with players of the synthetic biology market, have stepped forward to contribute to worldwide research efforts by providing synthetic biology for developing test kits, treatments, and vaccines to target the infection caused by the coronavirus.

Synthetic biology is highlighted as one of the emerging technologies in a report from the European Parliament.

It can fight the COVID-19 pandemic.

The National Institute of Health in the US has also identified synthetic biology as one way to speed up vaccine development.The Factors such as a wide range of applications of synthetic biology, the rising R funding and growing initiatives in synthetic biology, declining cost of DNA sequencing and synthesizing, and increasing investments in the market are propelling the growth of this market.

However, biosafety, biosecurity, and ethical concerns related to synthetic biology would hamper the growth of this market.The oligonucleotides and synthetic DNA segment accounted for the largest share of the tool segment in the synthetic biology market in 2020.On the basis of tool, the market is broadly segmented into oligonucleotides & synthetic DNA, enzymes, cloning technology kits, synthetic cells, chassis organisms, and xeno-nucleic acids.

In 2020, oligonucleotides & synthetic DNA accounted for the largest share of the market for tools.

Benefits offered by robotic systems in pharmaceutical manufacturing is a key factor driving the growth of pharmaceutical robots market.

The base year considered for the study is 2015, and the forecast has been provided for the period between 2016 and 2021.

[218 Pages Report] MarketsandMarkets forecasts the pharmacy automation market is estimated to grow from USD 3.63 billion in 2017 to USD 5.38 Billion by 2022, at a Compound Annual Growth Rate (CAGR) of 8.2% during the forecast period.The major factors that are expected to be driving the pharmacy automation market are the growing need to minimize medication errors, rapid decentralization of pharmacies, rising geriatric population and rising labor cost.

On the other hand, reluctance among the healthcare organizations to adopt pharmacy automation systems is expected to restrain the overall market growth to a certain extent during the forecast period.

The objective of the report is to define, describe, and forecast the pharmacy automation market size based on product, end user, and region.Market DynamicsGrowing Need to Minimize Medication ErrorsDecentralization of PharmaciesRising Geriatric PopulationRising Labor CostBased on product, the pharmacy automation market is segmented into automated medication dispensing systems, automated packaging and labelling systems, automated table top counters, automated medication compounding systems, automated storage and retrieval systems, and other pharmacy automation systems.

Automated medication dispensing systems accounted for the largest share of the pharmacy automation market in 2016.

The major factors that are expected to be driving the high content screening market are need for cost containment in pharma R, growth in funding for cellular research, and technological advancements in HCS solutions are expected to support the growth of the HCS market during the forecast period.

On the other hand, the high cost of HCS instruments and the dearth of knowledgeable and skilled personnel for the operation of high-content screening instruments are expected to restrain the market growth to a certain extent.

[166 Pages Report] MarketsandMarkets forecasts the high content screening market to grow from USD 557.1 million in 2017 to USD 909.0 million by 2022, at a Compound Annual Growth Rate (CAGR) of 10.3% during the forecast periodThe HCS instruments market accounted for the largest share of HCS market primarily attributed to advances in instrumentation and automation techniques and high prices of the HCS instruments.

The software segment is expected to register the highest growth during the forecast period.Market DynamicsNeed for Cost Containment in Pharmaceutical RGovernment Funding and Venture Capital Investments Across Developed MarketsAdvancements in Informatics Solutions and Imaging InstrumentsNeed for cost containment in pharmaceutical RAccording to the California Biomedical Research Association (CBRA), it takes an average of 12 years for a drug to travel from the research lab to the patient, including 1–6 years for toxicology studies alone.

In addition, only five in 5,000, or 10%, of the drugs that begin preclinical testing ever make it to human testing.

The high cost and long duration of drug development are compelling pharmaceutical companies to revise their R expenditure.Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=42710391HCS is used in several stages of the drug discovery process, including primary and secondary screening, target identification and validation and toxicity studies.

Bioinformatics is increasingly being used to identify genes in DNA sequences.

This assists in developing better treatments and diagnostic tests.

Recently, due to significant reductions in costs of sequencing, many scientific research institutes and biotech companies have undertaken initiatives to perform sequencing studies at their own facilities.According to the new market research report ” Bioinformatics Market by Product & Service (Knowledge Management Tools, Data Analysis Platforms (Structural & Functional), Services), Applications (Genomics, Proteomics & Metabolomics), & Sectors (Medical, Academics, Agriculture)”, global bioinformatics market is expected to account for USD 7,063.7 billion in 2018.

With the introduction of upcoming technologies such as nanopore sequencing (third generation sequencing technique) and cloud computing, the market is expected to offer significant opportunities for manufacturers of bioinformatics solutions.Expected Revenue Growth:[195 Pages Report] The global bioinformatics market is expected to account for USD 7,063.7 billion in 2018.

It includes collection, storage, retrieval, manipulation, and modelling of data for analysis, visualization, or prediction through algorithms and software.However, factors such as a dearth of skilled personnel to ensure proper use of bioinformatics tools and lack of integration of a wide variety of data generated through various bioinformatics platforms are hindering market growth.Browse in-depth TOC on “Bioinformatics Market”189 – Tables27 – Figures195 – PagesDownload PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=39By Product and Services, bioinformatics platforms segment is expected to be the fastest-growing segment in the forecast periodKnowledge management tools commanded the largest market share in the global bioinformatics market in 2018, while the bioinformatics platforms segment is expected to be the fastest-growing segment in the forecast period.

In addition, the use of bioinformatics platforms is increasing in the drug discovery & development process, which is contributing to market growth.By Application, the metabolomics segment is expected to grow at the highest CAGR during the forecast periodFactors such as the availability of research funding and government support are fueling market growth.

This market research study involved the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global biologics safety testing market.

[185 Pages Report] The global biologics safety testing market is projected to reach USD 6.2 billion by 2026 from USD 3.4 billion in 2021, at a CAGR of 12.4% during the forecast period.The growth of the global biologics safety testing market is driven by factors such as the growth in the biologics and biosimilars markets, growing concerns over cell culture contamination, and rising biopharmaceuticals R activities and investments.

In addition, emerging markets and increasing biopharmaceutical outsourcing are expected to provide significant growth opportunities for players in the Biologics safety testing market.Market DynamicsGrowth in the biosimilars and biologics marketsGrowing concerns over cell culture contaminationRising biopharmaceuticals R activities and investmentsEmerging markets offer lucrative opportunitiesIncreasing biopharmaceutical outsourcingMany companies are investing heavily in the development of biologics and biosimilars.

Biologics are expected to contribute around half of the revenue generated by the top 100 pharmaceutical products in the coming years.Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=34624144Covid-19 Impact On The Global Biologics Saftey Testing MarketCOVID-19 is an infectious disease caused by the most recently discovered novel coronavirus.

A mix of established pharmaceutical and biopharmaceutical companies, along with the players of the Biologics safety testing market, have stepped forward to contribute to worldwide research efforts by providing biologics safety testing for developing safety test kits and testing for treatments and vaccines manufacturing that target the infection caused by the novel Coronavirus.Based on application, the biologics safety testing market is segmented into monoclonal antibodies manufacturing, vaccines manufacturing, blood and blood products manufacturing, cellular and gene therapy products manufacturing, and other applications.

Rest of the World (RoW)5.

Growth of the market is mainly driven by the increasing use of medical imaging modalities due to the rising incidence of chronic diseases, increasing concerns over radiation dose exposure, growth in the installed base of radiology equipment, and growing awareness on radiation dose management.

[226 Pages Report] The global radiation dose management market size is projected to reach USD 423 million by 2025 from USD 220.22 million in 2020, at a CAGR of 13.9% during the forecast period.The major factors that are expected to be driving the pharmacy automation market are the growing need to minimize medication errors, rapid decentralization of pharmacies, rising geriatric population and rising labor cost.

On the other hand, reluctance among the healthcare organizations to adopt pharmacy automation systems is expected to restrain the overall market growth to a certain extent during the forecast period.

The objective of the report is to define, describe, and forecast the pharmacy automation market size based on product, end user, and region.Market DynamicsIncreasing use of medical imaging modalities due to the growing burden of chronic diseasesGrowing concerns over radiation exposureGrowing installation base of radiology equipmentGrowing awareness about radiation dose managementCOVID -19 IMPACT ON THE RADIATION DOSE MANAGEMENT MARKETSeveral countries across the globe have seen non-urgent diagnostic imaging surgeries being postponed due to the pandemic.

These procedures utilize additional resources and increase the risk of complications; depending on the procedure, they also increase the chance of needing equipment, resources, or materials such as hospital beds and PPE.Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=71522890Based on product & service, the radiation dose management market is segmented into radiation dose management solutions and radiation dose management services.

The radiation dose management solutions segment is projected to witness the highest growth during the forecast period.

Growth in this market is driven by the high risk of chromosomal abnormalities with increasing maternal age, growing preference for non-invasive techniques over invasive methods, improving reimbursement scenario for NIPT, and increasing awareness of NIPT.

However, a dearth of skilled professionals is restraining the growth of this market.

[144 Pages Report] The global non-invasive prenatal testing (NIPT) market is estimated to reach USD 7.3 billion by 2024 from USD 3.9 billion in 2019, at a CAGR of 13.5% during the forecast period.The study involved four major activities in estimating the current size of the global non-invasive prenatal testing market.

The next step was to validate these findings, assumptions, and sizing values with industry experts across the value chain through primary research.Market DynamicsHigh Risk of Chromosomal Abnormalities With Increasing Maternal AgeGrowing Preference for Noninvasive Techniques Over Invasive MethodsImproving Reimbursement Scenario for NIPTPrograms Focusing on Increasing the Awareness of NIPTThe trisomy applications segment accounted for the largest share of the global NIPT market in 2018.Based on application, the non-invasive prenatal testing (NIPT) market is segmented into trisomy, microdeletion syndrome, and other applications (gender identification and the detection of monogenic disorders, Klinefelter syndrome, and Rhesus (Rh) blood type).

This segment is also estimated to grow at the highest CAGR during the forecast period.

The large share and high growth of this segment can primarily be attributed to factors such as the increasing maternal age and the rising incidence of chromosomal abnormalities.Download PDF Brochure @  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=145607690By method, the NIPT products market is segmented into ultrasound detection, biochemical screening tests, and cell-free DNA in maternal plasma tests.

The Growth in this HIE Market can be attributed to factors such as growing need to curtail healthcare costs, focus on patient-centric care delivery, growing adoption of EHRs and other HCIT solutions, government initiatives for enhancing patient care and safety, government funding for healthcare interoperability.However, data privacy concerns, need for significant investments in infrastructure development and high cost of deployment, lack of true interoperable solutions are expected to hinder the market growth.According to the new market research report “Health Information Exchange (HIE) Market by Set Up Type (Public, Private), Implementation Model (Federated, Hybrid), Type (Pull, Push), Application (Web Portal, Secure Messaging), Solution (Portal, Platform Centric), End User – Global Forecast to 2025″, published by MarketsandMarkets™, the global Health Information Exchange Market is expected to reach 2.0 billion by 2025 from an estimated USD 1.1 billion in 2020 at a CAGR of 12.2% during the forecast period.COVID-19 Impact on the Health information exchange MarketThe COVID-19 pandemic has created technological shifts crucial to providing better care.

The crisis has made complying with data interoperability a priority for most healthcare institutions.

It has also increased the need for social distancing among physicians and patients, which has driven the demand for remote patient monitoring and telehealth solutions and the need for the accurate and timely exchange of patient health records.

These solutions allow a seamless exchange and interpretation of health-related data among healthcare organizations and patients for clinical decision-making and other applications.Browse in-depth TOC on “Health Information Exchange (HIE) Market”141 – Tables36 – Figures199 – PagesDownload PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=249987292The health information exchange market includes Tier I and II vendors Epic Systems Corporation (US), Cerner Coporation (US), MEDITECH(US), and Intersystems Corporation (US)  among others.

The companies have a large market spread across various countries in North America, Europe, Asia Pacific, and the Rest of the World.The private HIE segment is expected to account for the largest share during the forecast periodBased on the setup type, the health information exchange market is segmented into public and private HIE.

The large share and high growth can be attributed to the various advantages it offers as compared to public HIEs, such as additional functionalities and strong technical support.The hybrid model is expected to grow at the highest rate during the forecast periodBased on the implementation model, the health information exchange market is segmented into centralized/consolidated model, federated/decentralized, hybrid models.

Various secondary sources such as associations (including Food and Drug Administration (FDA), European Association for Medical Device Reprocessing (EAMDR), Association of Medical Device Reprocessors (AMDR), and Canadian Association of Medical Device Reprocessing (CAMDR)), directories, industry journals, databases, and annual reports of the companies have been used to identify and collect information useful for the study of this market.

Top-down and bottom-up approaches were used to validate the size of the global medical device reprocessing market and estimate the size of other dependent submarkets.According to the new market research report “Medical Device Reprocessing Market by Product (Reprocessed Device (Catheter, Endoscope, Laparoscopic Instruments, Biopsy, Pulse Oximeter), Service), Application (Cardiology, Gastroenterology, Arthroscopy, Orthopedic, Anesthesia)”,  published by MarketsandMarkets™, medical device reprocessing market is projected to be valued at USD 823.5 Million in 2017 and is expected to grow at a CAGR of 16.3% during the forecast period to reach to USD 1,754 Million by 2022.

Base year considered for the report is 2016.Major Growth Drivers:The key factors driving the growth of this market include the low prices of reprocessed devices as compared to new ones and the pressure to reduce the volume of medical waste generated.

The medical device reprocessing includes cleaning, disinfection, inspection, sterilization, and repackaging of used medical devices for its reuse to diagnose and treat multiple patients.Expected Revenue Growth:[145 Pages Report] The global medical device reprocessing market is projected to be valued at USD 823.5 Million in 2017 and is expected to grow at a CAGR of 16.3% during the forecast period to reach to USD 1,754 Million by 2022.

To analyze market opportunities for stakeholders and provide details of the competitive landscape of market leaders5.

To forecast the size of the market with respect to four main regions—North America, Europe, Asia-Pacific, and the Rest of the WorldBrowse in-depth TOC on ” Medical Device Reprocessing Market “75 – tables24 – figures145 – pagesDownload PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=583The growth of this market is majorly driven by the increased utilization of the low priced reprocessed medical devices as compared to new devices, increased efforts towards reducing regulated medical waste (RMW), and rising number of surgical procedures associated with the growing prevalence of chronic diseases.

A robotic system is a type of automation that has multiple axes of motion and can be programmed to perform a function.

Some of the benefits of automation include efficiency, saving workers from hazardous environments or repetitive tasks, reducing training overhead, eliminating human error, increasing repeatability and reproducibility, and in cleanrooms, removing the potential for human contamination.

[141 Pages Report] The overall pharmaceutical robotic systems market is expected to grow from USD 64.37 million in 2016 to USD 119.46 million by 2021, at a CAGR of 13.2% from 2016 to 2021.Benefits offered by robotic systems in pharmaceutical manufacturing is a key factor driving the growth of pharmaceutical robots market.

The base year considered for the study is 2015, and the forecast has been provided for the period between 2016 and 2021.Market DynamicsBenefits offered by robotic systems in pharmaceutical manufacturingConferences and exhibitions to raise awareness of robotic systems in pharmaceutical manufacturingRobotic systems provide various benefits to pharmaceutical manufacturing such as lesser space utilization, reduced production downtime, no labor turnover, enhanced health and safety, better waste management, increased production flexibility, improved production output and product quality, and lower operating costs.

With the growing pharmaceutical industry and the various benefits offered by robotic automation, the adoption of robots is likely to increase in the coming years.Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=210985096On the basis of application, the global pharmaceutical robotic systems market is segmented into picking and packaging, inspection of pharmaceutical drugs, and laboratory applications.

The picking and packaging segment accounted for the largest share of the global pharmaceutical robotic systems market.